Search

Your search keyword '"Lianidou, Evi S."' showing total 312 results
Start Over Author "Lianidou, Evi S."
312 results on '"Lianidou, Evi S."'

1. SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions

Author

Galani, Aikaterini, Aalizadeh, Reza, Kostakis, Marios, Markou, Athina, Alygizakis, Nikiforos, Lytras, Theodore, Adamopoulos, Panagiotis G., Peccia, Jordan, Thompson, David C., Kontou, Aikaterini, Karagiannidis, Apostolos, Lianidou, Evi S., Avgeris, Margaritis, Paraskevis, Dimitrios, Tsiodras, Sotirios, Scorilas, Andreas, Vasiliou, Vasilis, Dimopoulos, Meletios-Athanasios, and Thomaidis, Nikolaos S.

Published
2022
Full Text
View/download PDF

18. SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions

Author

Galani, Aikaterini Aalizadeh, Reza Kostakis, Marios Markou, Athina Alygizakis, Nikiforos Lytras, Theodore Adamopoulos, Panagiotis G. Peccia, Jordan Thompson, David C. Kontou, Aikaterini Karagiannidis, Apostolos Lianidou, Evi S. and Avgeris, Margaritis Paraskevis, Dimitrios Tsiodras, Sotirios and Scorilas, Andreas Vasiliou, Vasilis Dimopoulos, Meletios-Athanasios Thomaidis, Nikolaos S. and Galani, Aikaterini Aalizadeh, Reza Kostakis, Marios Markou, Athina Alygizakis, Nikiforos Lytras, Theodore Adamopoulos, Panagiotis G. Peccia, Jordan Thompson, David C. Kontou, Aikaterini Karagiannidis, Apostolos Lianidou, Evi S. and Avgeris, Margaritis Paraskevis, Dimitrios Tsiodras, Sotirios and Scorilas, Andreas Vasiliou, Vasilis Dimopoulos, Meletios-Athanasios Thomaidis, Nikolaos S.

Abstract

We measured SARS-CoV-2 RNA load in raw wastewater in Attica, Greece, by RT-qPCR for the environmental surveillance of COVID-19 for 6 months. The lag between RNA load and pandemic indicators (COVID-19 hospital and intensive care unit (ICU) admissions) was calculated using a grid search. Our results showed that RNA load in raw wastewater is a leading indicator of positive COVID-19 cases, new hospitalization and admission into ICUs by 5, 8 and 9 days, respectively. Modelling techniques based on distributed/fixed lag modelling, linear regression and artifi-cial neural networks were utilized to build relationships between SARS-CoV-2 RNA load in wastewater and pandemic health indicators. SARS-CoV-2 mutation analysis in wastewater during the third pandemic wave revealed that the alpha-variant was dominant. Our results demonstrate that clinical and environmental surveillance data can be combined to create robust models to study the on-going COVID-19 infection dynamics and provide an early warning for increased hospital admissions. (c) 2021 Elsevier B.V. All rights reserved.

Published
2022

26. Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer

Author

Tserpeli, Victoria, primary, Stergiopoulou, Dimitra, additional, Londra, Dora, additional, Giannopoulou, Lydia, additional, Buderath, Paul, additional, Balgkouranidou, Ioanna, additional, Xenidis, Nikolaos, additional, Grech, Christina, additional, Obermayr, Eva, additional, Zeillinger, Robert, additional, Pavlakis, Kitty, additional, Rampias, Theodoros, additional, Kakolyris, Stylianos, additional, Kasimir-Bauer, Sabine, additional, and Lianidou, Evi S., additional

Published
2021
Full Text
View/download PDF

29. USP44 Promoter Methylation in Plasma Cell-Free DNA in Prostate Cancer

Author

Londra, Dora Mastoraki, Sophia Bournakis, Evangelos and Zavridou, Martha Thanos, Anastasios Rampias, Theodoros and Lianidou, Evi S.

Abstract

Simple Summary Liquid biopsy provides real-time monitoring of tumor evolution and response to therapy through analysis of circulating tumor cells (CTCs) and plasma-circulating tumor DNA (ctDNA). USP44 is a member of family proteins deubiquitinases, and plays an important role in cell growth; however, its accurate role in other cellular networks is under research. In this study, we examined for the first time USP44 promoter methylation in plasma cell-free DNA (cfDNA) of patients with prostate cancer (early stage n = 32, metastatic n = 39) and 10 healthy donors (HD). USP44 promoter methylation was detected in plasma cell-free DNA by a newly developed highly specific and sensitive real-time MSP method. We report for the first time that detection of USP44 promoter methylation in plasma cell free DNA provides significant prognostic information in metastatic prostate cancer. Liquid biopsy provides real-time monitoring of tumor evolution and response to therapy through analysis of circulating tumor cells (CTCs) and plasma-circulating tumor DNA (ctDNA). USP44 is a critical gene which plays an important role in cell proliferation; however, its accurate role in other cellular networks is under research. USP44 promoter methylation has been so far reported in colorectal neoplasia and metastatic breast cancer. In this study, we examined for the first time USP44 promoter methylation in plasma cell-free DNA (cfDNA) of patients with prostate cancer (early stage n = 32, metastatic n = 39) and 10 healthy donors (HD). USP44 promoter methylation was detected in plasma cell-free DNA by a newly developed highly specific and sensitive real-time MSP method. Our findings indicate that USP44 promoter is methylated in plasma cell-free DNA of metastatic prostate cancer patients and that detection of USP44 promoter methylation is significantly associated with overall survival (OS) (p = 0.008). We report for the first time that detection of USP44 promoter methylation in plasma cell free DNA provides significant prognostic information in metastatic prostate cancer.

Published
2021

31. A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer

Author

Strati, Areti, primary, Zavridou, Martha, additional, Kallergi, Galatea, additional, Politaki, Eleni, additional, Kuske, Andra, additional, Gorges, Tobias M, additional, Riethdorf, Sabine, additional, Joosse, Simon A, additional, Koch, Claudia, additional, Bohnen, Anna-Lena, additional, Mueller, Volkmar, additional, Koutsodontis, George, additional, Kontopodis, Emmanouil, additional, Poulakaki, Nikiforita, additional, Psyrri, Amanda, additional, Mavroudis, Dimitris, additional, Georgoulias, Vasilis, additional, Pantel, Klaus, additional, and Lianidou, Evi S, additional

Published
2021
Full Text
View/download PDF

33. A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer

Author

Strati, Areti Zavridou, Martha Kallergi, Galatea Politaki, Eleni Kuske, Andra Gorges, Tobias M. Riethdorf, Sabine and Joosse, Simon A. Koch, Claudia Bohnen, Anna-Lena Mueller, Volkmar Koutsodontis, George Kontopodis, Emmanouil and Poulakaki, Nikiforita Psyrri, Amanda Mavroudis, Dimitris and Georgoulias, Vasilis Pantel, Klaus Lianidou, Evi S. and Strati, Areti Zavridou, Martha Kallergi, Galatea Politaki, Eleni Kuske, Andra Gorges, Tobias M. Riethdorf, Sabine and Joosse, Simon A. Koch, Claudia Bohnen, Anna-Lena Mueller, Volkmar Koutsodontis, George Kontopodis, Emmanouil and Poulakaki, Nikiforita Psyrri, Amanda Mavroudis, Dimitris and Georgoulias, Vasilis Pantel, Klaus Lianidou, Evi S.

Abstract

BACKGROUND: Circulating tumor cell (CTC) analysis is highly promising for liquid biopsy-based molecular diagnostics. We undertook a comprehensive molecular analysis of in vivo isolated CTCs in breast cancer (BrCa). METHODS: In vivo isolated CTCs from 42 patients with early and 23 patients with metastatic breast cancer (MBC) were prospectively collected and analyzed for gene expression, DNA mutations, and DNA methylation before and after treatment. 19 healthy donor (HD) samples were analyzed as a control group. In identical blood draws, CTCs were enumerated using CellSearch (R) and characterized by direct IF staining. RESULTS: All 19 HD samples were negative for CK8, CK18, CK19, ERBB2, TWIST1, VEGF, ESR1, PR, and EGFR expression, while CD44, CD24, ALDH1, VIM, and CDH2 expression was normalized to B2M (reference gene). At least one gene was expressed in 23/42 (54.8%) and 8/13 (61.5%) CTCs in early BrCa before and after therapy, and in 20/23 (87.0%) and 5/7 (71.4%) MBC before and after the first cycle of therapy. PIK3CA mutations were detected in 11/42 (26.2%) and 3/13 (23.1%) in vivo isolated CTCs in early BrCa before and after therapy, and in 11/23 (47.8%) and 2/7 (28.6%) MBC, respectively. ESR1 methylation was detected in 5/32 (15.7%) and 1/10 (10.0%) CTCs in early BrCa before and after therapy, and in 3/15(20.0%) MBC before the first line of therapy. The comprehensive molecular analysis of CTC revealed a higher sensitivity in relation to CellSearch or IF staining when based on creatine kinase selection. CONCLUSIONS: In vivo-CTC isolation in combination with a comprehensive molecular analysis at the gene expression, DNA mutation, and DNA methylation level comprises a highly powerful approach for molecular diagnostic applications using CTCs.

Published
2021

49. Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer Patients

Author

Xenidis, Nikos, Perraki, Maria, Kafousi, Maria, Apostolaki, Stella, Bolonaki, Irene, Stathopoulou, Aliki, Kalbakis, Kostas, Androulakis, Nikos, Kouroussis, Charalambos, Pallis, Thanos, Christophylakis, Charalambos, Argyraki, Katerina, Lianidou, Evi S., Stathopoulos, Stathis, Georgoulias, Vassilis, and Mavroudis, Dimitris

Published
2006
Full Text
View/download PDF

50. Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectives

Author

Alygizakis, Nikiforos Markou, Athina N Rousis, Nikolaos I Galani, Aikaterini Avgeris, Margaritis Adamopoulos, Panagiotis G Scorilas, Andreas Lianidou, Evi S Paraskevis, Dimitrios Tsiodras, Soritios others and Alygizakis, Nikiforos Markou, Athina N Rousis, Nikolaos I Galani, Aikaterini Avgeris, Margaritis Adamopoulos, Panagiotis G Scorilas, Andreas Lianidou, Evi S Paraskevis, Dimitrios Tsiodras, Soritios others

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results